Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Price History  |  Ratios  |  Insiders

Breaking & Recent News Allarity Therapeutics Inc ALLR

Healthcare Biotechnology
Allarity Therapeutics, Inc., a clinical-stage precision medicine pharmaceutical company, focuses on developing novel anti-cancer therapeutics for patients with unmet medical needs. The company develops drugs for the personalized treatment of cancer using drug specific companion diagnostics generated by its proprietary drug response predictor technology. Its lead drug candidate includes... see more

Recent & Breaking News (NDAQ:ALLR)

Allarity Therapeutics Issues 2025 End of Year CEO Letter to Shareholders

GlobeNewswire December 31, 2025

Allarity Therapeutics Provides Third Quarter 2025 Financial Results and Provides Business Updates

GlobeNewswire November 14, 2025

Allarity Therapeutics Presents New Phase 2 Clinical Data for Stenoparib/2X-121 Showing Landmark Median Overall Survival Has Now Surpassed 25 Months

GlobeNewswire September 22, 2025

Allarity Therapeutics CEO to Present at Biomarkers & Precision Medicine 2025

GlobeNewswire September 17, 2025

Allarity Therapeutics Granted FDA Fast Track Designation for Stenoparib for the Treatment of Advanced Ovarian Cancer

GlobeNewswire August 26, 2025

Allarity Therapeutics Provides Second Quarter 2025 Update, Highlighting Clinical Progress, IP Expansion, and New Partnerships

GlobeNewswire August 15, 2025

Allarity Therapeutics Announces New Licensing and Laboratory Services Agreement to Expand DRP® Platform Utilization

GlobeNewswire July 15, 2025

Allarity Therapeutics Announces Appointment of Jeff Ervin as Chief Financial Officer

GlobeNewswire July 7, 2025

Allarity Therapeutics Receives Australian Patent Acceptance Notice for Stenoparib DRP® Companion Diagnostic

GlobeNewswire June 30, 2025

Allarity Therapeutics Announces Dosing of Second Patient in New Phase 2 Trial of Stenoparib in Advanced Ovarian Cancer

GlobeNewswire June 27, 2025

Allarity Therapeutics Announces Changes to Board of Directors

GlobeNewswire June 11, 2025

Allarity Therapeutics Announces Research Collaboration with Indiana Biosciences Research Institute to Further Advance Understanding of Stenoparib's Unique, Dual Therapeutic Mechanism of Action

GlobeNewswire June 4, 2025

Allarity Therapeutics Announces First Patient Enrolled in New Phase 2 Clinical Trial Protocol of Stenoparib in Advanced Ovarian Cancer

GlobeNewswire June 2, 2025

Allarity Therapeutics Announces Participation in Pharma Partnering Summit US

GlobeNewswire May 12, 2025

Allarity Therapeutics Provides First Quarter 2025 Update, Highlighting Continued Stenoparib Benefit and Upcoming Trial Enrollment

GlobeNewswire May 9, 2025

Allarity Therapeutics Presents Novel Drug Response Predictor-DRP®-for Daratumumab in Multiple Myeloma at AACR 2025

GlobeNewswire April 25, 2025

ALLR Shareholders are Encouraged to Join Allarity Therapeutics, Inc. Securities Fraud Investigation with the Schall Law Firm

PR Newswire April 14, 2025

Allarity Therapeutics Reports Full Year 2024 Financial Results and Provides a Business Update

GlobeNewswire March 31, 2025

ALLR Shareholders are Encouraged to Join Allarity Therapeutics, Inc. Securities Fraud Investigation with the Schall Law Firm

PR Newswire March 25, 2025

Allarity Therapeutics Launches Comprehensive Effort to Combat Potential Illegal Naked Short Selling of Its Shares

GlobeNewswire March 24, 2025

Podcasts